OKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street Zen

Key Points

• OKYO Pharma has been upgraded to a "hold" rating by Wall Street Zen in a recent report.
• HC Wainwright has reiterated a "buy" rating on OKYO Pharma, setting a price target of $7.00.
• The company is focused on developing therapeutics for inflammatory eye diseases and its lead product candidate, OK-101, is currently in Phase II clinical trials.

Wall Street Zen upgraded shares of OKYO Pharma (NASDAQ:OKYO - Free Report) to a hold rating in a research note released on Saturday.

Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of OKYO Pharma in a research report on Monday, May 5th.

OKYO Pharma Stock Performance

NASDAQ:OKYO traded down $0.14 during trading hours on Friday, reaching $2.83. The stock had a trading volume of 43,225 shares, compared to its average volume of 170,415. The stock has a 50 day simple moving average of $2.66 and a 200 day simple moving average of $1.79. OKYO Pharma has a 12-month low of $0.85 and a 12-month high of $3.35.

Institutional Trading of OKYO Pharma

Large investors have recently bought and sold shares of the company. Dauntless Investment Group LLC purchased a new position in shares of OKYO Pharma in the first quarter valued at $2,526,000. FNY Investment Advisers LLC purchased a new position in shares of OKYO Pharma in the first quarter valued at $25,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of OKYO Pharma in the second quarter valued at $28,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.